TY - JOUR
T1 - Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans
AU - Endres, Christopher J.
AU - Coughlin, Jennifer M.
AU - Gage, Kenneth L.
AU - Watkins, Crystal C.
AU - Kassiou, Michael
AU - Pomper, Martin G.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.
AB - Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.
KW - Dosimetry
KW - Microglia
KW - PET/CT
KW - Radiotracer tissue kinetics
KW - Translocator protein
UR - http://www.scopus.com/inward/record.url?scp=84856806258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856806258&partnerID=8YFLogxK
U2 - 10.2967/jnumed.111.094565
DO - 10.2967/jnumed.111.094565
M3 - Article
C2 - 22241913
AN - SCOPUS:84856806258
SN - 0161-5505
VL - 53
SP - 330
EP - 335
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -